← Human Trials & Peer-Reviewed Studies
PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes
Plain-language guide to PMID 39316289 (2024): clinical trial, phase iv study of Semaglutide in 333 participants.
Key Facts
- PMID
- 39316289
- Journal
- Advances in therapy
- Year
- 2024
- Study type
- Clinical Trial, Phase IV
- Authors
- Saravanan P et al. (9 authors)
- DOI
- 10.1007/s12325-024-02973-z
- Registered trial
- NCT04862923
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Semaglutide, published as a clinical trial, phase iv.
Oral semaglutide provides an alternative to injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treatment of type 2 diabetes (T2D).
The PIONEER REAL studies evaluate clinical outcomes of oral semaglutide treatment of T2D in a real-world setting.
Who Took Part
The abstract describes 333 participants taking part.
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks.
Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication.
How the Study Was Run
The primary endpoint was change in glycated haemoglobin (HbA1C) from baseline to end of study (EOS).
Treatment satisfaction was assessed by Diabetes Treatment Satisfaction Questionnaire (DTSQ) status and change.
What Was Measured
The PIONEER REAL studies evaluate clinical outcomes of oral semaglutide treatment of T2D in a real-world setting.
PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Hypoglycemic Agents, Patient Satisfaction and United Kingdom.
Author keywords: Body weight, GLP-1 receptor agonist, Glucose-lowering medication, Glycaemic control, HbA1C and Incretin therapy.
What This Means in Plain Language
This is a clinical trial, phase iv of Semaglutide in 333 participants.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2024 (Advances in therapy), a journal based in United States.
More context: the Semaglutide compound page.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.